TREACE MEDICAL CONCEPTS, INC. (TMCI)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Revenue | 47,387 | 52,570 | 45,086 | |
| Cost of goods sold | 9,635 | 10,677 | 8,954 | |
| Gross profit | 37,752 | 41,893 | 36,132 | |
| Sales and marketing | 33,084 | 36,122 | 32,775 | |
| Research and development | 5,498 | 5,562 | 4,963 | |
| General and administrative | 16,144 | 15,791 | 13,528 | |
| Total operating expenses | 54,726 | 57,475 | 51,266 | |
| Loss from operations | -16,974 | -15,582 | -15,134 | |
| Other income, net | 122 | 130 | 20 | |
| Interest income | 775 | 841 | 1,067 | |
| Interest expense | 1,321 | 1,311 | 1,313 | |
| Other non-operating income (expense), net | -424 | -340 | -226 | |
| Net loss | -17,398 | -15,922 | -15,360 | |
| Unrealized gain (loss) on marketable securities | -7 | -40 | 217 | |
| Comprehensive loss | -17,405 | -15,962 | -15,143 | |
| Net loss per share attributable to common stockholders, basic | -0.28 | -0.25 | -0.25 | |
| Net loss per share attributable to common stockholders, diluted | -0.28 | -0.25 | -0.25 | |
| Weighted-average common stock outstanding, basic | 63,006,891 | 62,661,447 | 62,229,463 | |
| Weighted-average common stock outstanding, diluted | 63,006,891 | 62,661,447 | 62,229,463 | |